cyp2d6 การใช้

• Race is a factor in the occurrence of CYP2D6 variability.
• CYP2D6 converts codeine into morphine, which then undergoes glucuronidation.
• More than 100 CYP2D6 genetic variants have been identified.
• The substance is metabolised in the liver, mainly by the enzyme CYP2D6.
• CYP2C19 and CYP2D6 have been identified as the isoenzymes mainly responsible for demethylenation.
• CYP2D6 substrates can cause both drugs to build to dangerous levels in the bloodstream.
• A reduction in starting dose is recommended for patients who are CYP2D6 intermediate metabolizers.
• Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug metabolizing enzyme.
• They released their strongest Boxed Warning to elucidate the dangers of CYP2D6 UMs consuming codeine.
• CYP2D6 is primarily expressed in the liver.
• There is considerable variation in the efficiency and amount of CYP2D6 enzyme produced between individuals.
• Cytochrome isoforms affected by grapefruit components include CYP3A4, CYP1A2, CYP2C9, and CYP2D6.
• For example, CYP2D6 refers to family 2, subfamily D, and gene number 6.
• Certain CYP2D6 variations in breast cancer patients leads to a worse clinical outcome for tamoxifen treatment.
• A major metabolic catalyst involved is the cytochrome P450 enzyme known as 2D6, or CYP2D6.
• Up to 7 % of Caucasians are poor metabolizers of drugs metabolized by the CYP2D6 enzyme.
• It is highly inhibitors of CYP2D6.
• As escitalopram is only a weak inhibitor of CYP2D6, analgesia from tramadol may not be affected.
• The prevalence of CYP2D6 poor metabolizers is approximately 6 10 % in Asians ( 2 % ).
• The occurrence of CYP2D6 ultrarapid metabolizers appears to be greater among Middle Eastern and North African populations.